Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
Lene Hoimark, Torben Laursen, Jørgen RungbyDepartment of Biomedicine – Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkBackground: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9e9a08294b40482b99b4feb3ff8beb1c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9e9a08294b40482b99b4feb3ff8beb1c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9e9a08294b40482b99b4feb3ff8beb1c2021-12-02T06:08:30ZPotential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes1178-7007https://doaj.org/article/9e9a08294b40482b99b4feb3ff8beb1c2012-08-01T00:00:00Zhttp://www.dovepress.com/potential-role-of-linagliptin-as-an-oral-once-daily-treatment-for-pati-a10788https://doaj.org/toc/1178-7007Lene Hoimark, Torben Laursen, Jørgen RungbyDepartment of Biomedicine – Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkBackground: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 increases the levels of the incretin hormones glucagon-like peptide and glucose-dependent insulinotropic polypeptide by preventing their degradation.Objective: We reviewed the role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.Methods: A comprehensive literature search was performed using the term “linagliptin.” Original research articles and review articles were included in our examination.Results: Linagliptin has a similar mode of action as other gliptins, with comparable efficacy, safety profile, and tolerability. Differences in pharmacokinetic parameters that distinguish linagliptin from other gliptins include that linagliptin is not renally excreted and does not require dose reduction with renal impairment.Conclusion: Linagliptin is an oral, once-daily, antihyperglycemic agent that significantly reduces glycated hemoglobin (HbA1c) when used alone or in combination with other antidiabetic drugs in people with type 2 diabetes. Pharmacokinetics, such as the lack of renal excretion, distinguishes linagliptin from other gliptins.Keywords: DPP-4 inhibitors, linagliptin, type 2 diabetesHoimark LLaursen TRungby JDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2012, Iss default, Pp 295-302 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Hoimark L Laursen T Rungby J Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| description |
Lene Hoimark, Torben Laursen, Jørgen RungbyDepartment of Biomedicine – Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkBackground: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 increases the levels of the incretin hormones glucagon-like peptide and glucose-dependent insulinotropic polypeptide by preventing their degradation.Objective: We reviewed the role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.Methods: A comprehensive literature search was performed using the term “linagliptin.” Original research articles and review articles were included in our examination.Results: Linagliptin has a similar mode of action as other gliptins, with comparable efficacy, safety profile, and tolerability. Differences in pharmacokinetic parameters that distinguish linagliptin from other gliptins include that linagliptin is not renally excreted and does not require dose reduction with renal impairment.Conclusion: Linagliptin is an oral, once-daily, antihyperglycemic agent that significantly reduces glycated hemoglobin (HbA1c) when used alone or in combination with other antidiabetic drugs in people with type 2 diabetes. Pharmacokinetics, such as the lack of renal excretion, distinguishes linagliptin from other gliptins.Keywords: DPP-4 inhibitors, linagliptin, type 2 diabetes |
| format |
article |
| author |
Hoimark L Laursen T Rungby J |
| author_facet |
Hoimark L Laursen T Rungby J |
| author_sort |
Hoimark L |
| title |
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| title_short |
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| title_full |
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| title_fullStr |
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| title_full_unstemmed |
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| title_sort |
potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/9e9a08294b40482b99b4feb3ff8beb1c |
| work_keys_str_mv |
AT hoimarkl potentialroleoflinagliptinasanoraloncedailytreatmentforpatientswithtype2diabetes AT laursent potentialroleoflinagliptinasanoraloncedailytreatmentforpatientswithtype2diabetes AT rungbyj potentialroleoflinagliptinasanoraloncedailytreatmentforpatientswithtype2diabetes |
| _version_ |
1718400066068152320 |